Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
The EMPA-REG OUTCOME trial demonstrated that empagliflozin reduced cardiovascular death by 38% and heart failure hospitalisation by 35% in patients with type 2 diabetes and established cardiovascular disease — the first glucose-lowering agent to show a mortality benefit in a cardiovascular outcomes trial.
An ex-vivo study finds early empagliflozin dampens NLRP3 inflammasome activity in macrophages from post-MI diabetic patients, a mechanistic signal. PICO summary and commentary.
An RCT finds pentoxifylline reduces microalbuminuria, preserves eGFR, and improves left ventricular mass index over 12 months in advanced diabetic nephropathy, using surrogate endpoints. PICO summary and commentary.
A secondary analysis of the LeIKD trial finds longer endurance-exercise duration, more than intensity, improves fitness in older patients with coronary heart disease and type 2 diabetes, with early engagement predicting adherence. PICO summary and commentary.
The ABILITY Diabetes Global trial finds the Abluminus DES+ stent fails non-inferiority to the XIENCE everolimus-eluting stent in diabetes, with higher repeat revascularisation and target-lesion failure. PICO summary and commentary.
A 12-week dose-response trial finds purified anthocyanin supplements up to 640 mg/day do not improve arterial stiffness, blood pressure, or cardiovascular risk in older adults with high blood sugar. PICO summary and commentary.
A small post hoc COMET subgroup finds SGLT2 inhibitor use is associated with about half as many eye injections in diabetic macular edema with high blood pressure, an exploratory finding from 29 patients. PICO summary and commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
